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Hippocampal output is increased in affective disorders and is mediated by increased glutamatergic input via N-methyl-D-
aspartate (NMDA) receptor and moderated by antidepressant treatment. Activation of NMDA receptors by glutamate evokes the
release of nitric oxide (NO) by the activation of neuronal nitric oxide synthase (nNOS). The human hippocampus contains a high
density of NMDA receptors and nNOS-expressing neurons suggesting the existence of an NMDA-NO transduction pathway
which can be involved in the pathogenesis of affective disorders. We tested the hypothesis that nNOS expression is increased
in the human hippocampus from affectively ill patients. Immunocytochemistry was used to demonstrate nNOS-expressing
neurons in sections obtained from the Stanley Consortium postmortem brain collection from patients with major depression (MD,
N = 15), bipolar disorder (BD, N = 15), and schizophrenia (N = 15) and from controls (N = 15). nNOS-immunoreactive (nNOS-
IR) and Nissl-stained neurons were counted in entorhinal cortex, hippocampal CA1, CA2, CA3, and CA4 subfields, and
subiculum. The numbers of Nissl-stained neurons were very similar in different diagnostic groups and correlated significantly
with the number of nNOS-IR neurons. Both the MD and the BD groups had greater number of nNOS-IR neurons/400 µm2 in CA1
(mean ± SEM: MD = 9.2 ± 0.6 and BD = 8.4 ± 0.6) and subiculum (BD = 6.7 ± 0.4) when compared to control group (6.6 ± 0.5)
and this was significantly more marked in samples from the right hemisphere. These changes were specific to affective disorders
since no changes were seen in the schizophrenic group (6.7 ± 0.8). The results support the current view of the NMDA-NO
pathway as a target for the pathophysiology of affective disorders and antidepressant drug development.
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Introduction
Affective disorders, consisting mainly of major depres-
sion (MD) and bipolar disorder (BD), are among the most
severe diseases regarding disability-adjusted life years.
Despite better diagnostic options and increasing awareness
of MD and BD, their pathophysiology remains elusive (1).
Although almost certainly not solely responsible for the
myriad of symptoms observed in affective disorders, the
highly plastic, stress-sensitive hippocampal formation may
play a central role in affective disorders and in the action of
antidepressant drugs (1). Despite variation in the meas-
urement techniques and patient samples, structural mag-
netic resonance imaging studies have shown a significant
reduction of the hippocampal volume in subjects with a
history of affective disorder (2,3) although some studies
have reported negative findings (for a review, see Ref. 1).
It appears that hippocampal atrophy is observed preferen-
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tially in older, recurrently depressed subjects or subjects
who are refractory to antidepressant medications (4).
Experimentally, recurrent episodes of stress or elevated
glucocorticoid levels, also characteristic of MD, are associ-
ated with damage to the hippocampus. A loss of hippocam-
pal neurons is observed in monkeys submitted to pro-
longed psychosocial stress (5), whereas repeated restraint
stress in rats causes hippocampal CA3 pyramidal neurons
to undergo dendritic atrophy (6). These specific effects
have been suggested to be mediated by activation of the
hypothalamic–pituitary–adrenal axis acting in concert with
excitatory amino acid input via the N-methyl-D-aspartate
(NMDA) receptors (6).
In the brain, activation of the NMDA receptor by gluta-
mate can release nitric oxide (NO) by the activation of
calmodulin-calcium-dependent enzyme neuronal NO syn-
thase (nNOS) (7). nNOS catalyzes the oxidation of L-
arginine resulting in the formation of L-citrulline and NO,
which is a diffusible, free-radical messenger involved in
cell–cell communication and in numerous physiologic and
neuropsychiatric conditions (8,9).
The human hippocampus contains a high density of
NMDA receptors (10) and nNOS-expressing cells (11,12),
suggesting the existence of an NMDA-NO transduction
pathway. A crucial involvement of the NMDA-NO signaling
pathway in the pathophysiology of MD and in the mechan-
ism of action of antidepressant drugs has been suggested.
For example, NMDA receptor antagonists or NOS inhibi-
tors exhibit antidepressant-like properties in animal screen-
ing procedures (13-15). In addition, chronic treatment with
an NOS inhibitor also down-regulates ß-adrenergic recep-
tors in the frontal cortex of mice with a magnitude compa-
rable to imipramine (16). Clinically, ketamine, an NMDA
receptor antagonist, exhibits antidepressant activity in hu-
mans (17) as does methylene blue, an NOS inhibitor that
was found to be therapeutically effective in severe MD
(18). Finally, NO production may increase MD since the
patients show elevate plasma nitrate levels (19).
Studies in animals and humans have shown that the
hippocampus may be also an important site of action of
antidepressant drugs. Systemic and intra-hippocampal
administration of antidepressants prevent the anxiety incu-
bation effect of restraint stress and the development of
learned helplessness (15). Compellingly, in a PET study of
MD, Mayberg et al. (20) reported that clinical recovery on
fluoxetine was associated with a reduction in hippocampal
metabolism. This suggests that antidepressants decrease
hippocampal glutamatergic function and consequently NO
function since regional cortical metabolism mainly accounts
for glutamatergic neurotransmission (21). In this way, it
has been demonstrated that inhibition of the NMDA–NO
pathway appears to be one of the common actions of
antidepressants. Despite remarkable structural diversity,
three main kinds of antidepressants (desipramine, fluoxe-
tine and moclobemide) not only antagonized the NMDA-
induced lesion in PC12 cells, but also inhibited the function
of the NMDA–NO signal pathway (22). These findings are
consistent with the hypothesis first proposed by Paul and
Skolnick (14) that clinically used antidepressants may
share a common ability to block or down-regulate NMDA
glutamate receptor function.
In 1991, Deakin and Graeff (23) proposed that impair-
ment of hippocampal serotonin function weakens behav-
ioral resilience and results in MD. It has been long pro-
posed that impaired serotonin function in MD may be
mediated by stress-induced hypercortisolemia acting on
the high concentration of glucocorticoid receptors in the
hippocampus (1). Studies by Joca and Guimarães (15)
and others (6) have suggested that stress-induced changes
in hippocampal glutamate mechanisms may precede
changes in serotonin function.
Recently, it has been suggested that hippocampal NO
under non-stressed conditions may be under tonic inhibi-
tion by serotonergic neurons since an increased NOS
activity in the context of long-term 5-HT2 receptor inhibition
by ritanserin was observed in rats submitted to forced
swimming stress (24). Furthermore, this control might be
lost following states of serotonergic depletion, manifesting
as learned helplessness in animals and as depression in
humans.
Taken together, these findings suggest that activation of
the NMDA-NO pathway in the hippocampus can be involved
in the pathogenesis of affective disorders, possibly triggered
by glucocorticoid-mediated effects of stress and mediated
by impaired serotonin function. To investigate this hypo-
thesis in humans, we have tested the prediction that expres-
sion of nNOS is increased in the hippocampus obtained post
mortem from patients suffering from MD and BD.
Material and Methods
Tissue samples
Sections of the hippocampus were obtained from the
Stanley Medical Research Institute Neuropathology Con-
sortium (25). The material was obtained from 15 controls,
15 schizophrenic (SCZ), 15 MD, and 15 BD cases. Clinical
and demographical data are shown in Table 1. The psychi-
atric diagnosis was based on retrospective case note
review applying the criteria of the Diagnostic and Statisti-
cal Manual of Mental Disorders, 4th edition, 1994. Normal
controls had no history of neurological or psychiatric ill-
ness and neuropathological examination excluded Alzhei-
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mer’s disease or other cerebral pathology. The blocks
were fixed in 10% phosphate-buffered formalin, pH 7.0, for
1 to 31 months (average 8 months) and then embedded in
paraffin. Ten-micrometer sections were cut, mounted onto
gelatin-coated slides and stored at room temperature until
processed for nNOS immunohistochemistry.
Immunohistochemistry
The sections were initially dewaxed in two changes of
xylene (20 min each), rehydrated through graded alcohols
(100, 95, 80, and 70% ethanol, 5 min each), washed in
distilled water and pre-treated with 3% H2O2 in 50% metha-
nol (30 min) to decrease endogenous peroxidase. After
repeated washings (3X 15 min) in 0.1 M phosphate-buff-
ered saline (PBS), pH 7.4, the sections were incubated
with 5% normal goat serum in 0.1 M PBS containing 0.3%
Triton X-100 (PBS-T) for 1 h, to block nonspecific binding
sites. After rinsing in 0.1 M PBS-T, the sections were
incubated with the primary antibody (1:25, mouse anti-
nNOS, clone 16, Transduction Laboratories, San Diego,
CA, USA) for 40 h at 4°C. The primary antibody was
washed off with PBS-T (3X 15 min) and the sections were
then incubated with biotinylated goat anti-mouse immuno-
globulin G (1:100, PharmiGen, San Diego, CA, USA) for 2
h. They were then rinsed in PBS-T before 1-h incubation
with the avidin-biotin-peroxidase complex (1:500, Vector
Laboratories, Burlingame, CA, USA). Peroxidase activity
was developed using 3'-3' diaminobenzidine tetrahydro-
chloride (Sigma, USA) containing 0.05% H2O2. Finally, the
sections were dehydrated through a series of alcohols (70,
80, 95, and 100%), cleared in xylene and cover-slipped.
All reactions were carried out at the same time. Control
experiments were performed by omitting the primary anti-
body from the staining protocol. Adjacent sections were
stained with Cresyl violet (Nissl preparation) to help iden-
tify the location of the areas of interest.
Quantification
Microscope images were captured using a video cam-
era (Sony Hyper HAD) linked to a Leica DMRB (Nussloch,
Germany) microscope. nNOS-immunoreactivity (nNOS-
IR) was considered to be present when the cell showed a
clear unstained nucleus with granular immunoreactivity in
the cytoplasm. A two-dimensional counting method was
used to estimate immunopositive cell number within 400-
µm2 counting frames. Sections were viewed at 200X mag-
nification and images were captured using the Bioquant
(Nova Prime, Nashville, TN, USA) image analysis system.
Cells were counted in three to five fields (400 µm2) distrib-
uted across each area of interest per section, in three of the
four sections available per subject. The fourth section was
used for Nissl staining. All, nNOS-IR or Nissl-stained neu-
rons lying within counting frames were counted, excluding
those that crossed either the top or left side of the frame
(26). The images were carefully checked to ensure that all
neurons were recognized, that contiguous cells were split
and that the classification was corrected with the exclusion
of vessels and glia. These criteria were in accordance with
previously published studies (27,28). Cell counts were
carried out in a blind manner, without access to any infor-
mation about diagnosis by RMWO and the statistical anal-
ysis was carried out by JFWD who had no involvement in
counting.
The following regions were selected for analysis with
reference to the maps published by Paxinos and Mai (29):
CA4, CA3, CA2, and CA1 pyramidal layers of the hippo-
campus, pyramidal layer III of the subiculum and layers II
and III of the entorhinal cortex. Laminar boundaries were
confirmed with the aid of an encoder measuring the posi-
tion from the pial surface to the borders of each layer of
adjacent Nissl-stained sections which in all cases closely
overlay the nNOS sections. In the dentate gyrus, cells
were too densely packed to be counted. It was not possible
to identify all sub-regions in every subject because of
variation in the anteroposterior level of sectioning. How-
ever, there were no systematic group differences in sec-
tioning level.
Statistical analysis
To identify potential confounders to be included as
covariates, analysis of variance (ANOVA) was used to
determine group differences in age, pH, interval between
death and fixation (postmortem interval, PMI), and dura-
tion of storage in formalin. In addition, correlations were
computed between cell counts and the potential confound-
ers. The average number of nNOS-IR and Nissl-stained
neurons in each region was obtained, and the mean for
each of the four groups including controls, SCZ, MD, and
BD was further calculated. Data were analyzed using
ANOVA with factors for diagnosis (4 levels) and side (2
levels). Side was a between-subject factor because left-
and right-sided samples came from different brains since
in the Stanley collection one hemisphere is fixed and the
other frozen. In the SCZ group, there were insufficient
observations (N = 3-4 per region) in the right hippocampus
to permit reliable identification of lateralized abnormalities
(i.e., diagnosis by side interactions). Therefore, to deter-
mine whether diagnosis by side interactions in the main
analysis was due to lateralized changes in the MD and BD
groups, the main ANOVA was repeated including only MD,
BD and controls. The origin of diagnosis by side interac-
tions was determined by unilateral ANOVA with planned
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Labeling was seen predominantly in pyramidal neurons
although some interneurons were observed interspersed
between the pyramidal cells as well as in the stratum
radiatum, stratum lacunosum, and molecular layers. Granu-
lar immunoreactivity was seen in the cytoplasm of nNOS-
IR pyramidal neurons, showing the characteristic single
apical dendrite projecting perpendicular to the axis of the
hippocampus, as previously described by Doyle and Slater
(12). The granule cells of the dentate gyrus were weakly
immunostained for nNOS. Few nNOS-IR fibers were also
observed within the hippocampus.
No staining was observed when the primary antiserum
was omitted from the reaction solution (Figure 2).
Nissl-stained and nNOS-IR neurons
As shown in Table 2, the numbers of Nissl-stained
neurons in each sector were similar in the diagnostic
groups and there were no trends of main effects of diagno-
sis or interactions with side (P > 0.05). In most sectors, the
number of Nissl-stained neurons correlated significantly
with the number of nNOS-IR neurons.
In general, the MD and BD groups tended to have more
nNOS-IR neurons in all regions, especially in the right, and
this was most statistically compelling in CA1 and subicu-
lum while the SCZ group showed no trends of differences
from controls (Figure 3). The detailed results are pre-
sented below in the order of the multisynaptic hippocampal
pathway: entorhinal cortex-dentate gyrus-CA4-CA3-CA2-
CA1-subiculum.
There were no changes in cell neuron numbers in the
entorhinal cortex or in CA4, except for a main effect of
diagnosis after covarying for Nissl-stained neurons (F =
2.06; d.f. = 2.33; P < 0.05). The MD and BD groups had
greater numbers of nNOS-IR neurons in relation to Nissl-
stained neurons than controls (planned contrasts, P = 0.03
and P = 0.04, respectively). In CA3 there was a diagnosis
by side interaction (P = 0.04) in the main analysis but this
was due to nNOS-IR neuron numbers in the three subjects
for which there was no data in the right
hemisphere in the SCZ group. This interac-
tion was reduced in significance (P = 0.11)
when ANOVA was repeated without the SCZ
group. This trend probably reflects non-sig-
nificant increases in the right hemisphere
and decreases in the left hemisphere, espe-
cially in the BD group (Table 2). There were
no significant group differences in neuronal
number in CA2.
There were clear-cut changes in the num-
ber of nNOS-IR neurons in CA1 (Table 2,
Figure 3). The affectively ill groups, MD and
contrasts. Finally, analysis of covariance was carried out
for the affective and control groups with Nissl-stained
neuron numbers as a covariate.
To test the hypothesis that nNOS-IR neurons would be
reduced in subjects taking antidepressants and lithium,
counts from the BD and MD groups were combined and
compared in the treatment groups by the t-test. To test the
hypothesis that nNOS counts would be reduced in sub-
jects with a long duration of illness, Spearman correlations
between counts and duration of illness were calculated for
the combined BD plus MD group.
Results
Confounders
Age and gender did not differ between the diagnostic
and control groups and did not correlate with nNOS counts.
Patients tended to have longer PMIs and although the
main effect of diagnosis was not statistically significant,
planned contrasts showed that greater PMIs were signifi-
cant in the SCZ group (P = 0.04) and borderline in the BD
group (P = 0.07; Table 1). However, PMI did not correlate
with nNOS counts and was not retained as a covariate.
Brains that had been exposed to formalin for substantially
longer periods than brains from controls (main effect of
diagnosis: F = 3.55, d.f. = 3.56, P = 0.02) and 9 of the 15
controls had shorter fixation times than any of the SCZ
group and most of the other groups. However, time in
formalin did not correlate with nNOS counts and was not
included as a covariate. As an additional check, ANOVA
was repeated excluding controls since the clinical groups
did not differ in fixation time.
Distribution of nNOS-IR neurons in the hippocampal
formation
Neurons expressing nNOS-IR were distributed in all
fields of the hippocampus (CA4, CA3, CA2, and CA1),
dentate gyrus, subiculum, and entorhinal cortex (Figure 1).
Table 1. Clinical and demographic data of patients and controls from Stanley
Consortium postmortem brain collection.
                                             Psychiatric diagnosis
Negative SCZ MD BD
Age (years) 49.0 ± 2.5 45.6 ± 3.5 46.5 ± 2.4 41.0 ± 3.1
Gender (male/female) 10/5 9/6 9/6 11/4
PMI (h) 22.7 ± 2.2 33.7 ± 3.8a 27.5 ± 2.8 32.5 ± 4.2b
Data are reported as means ± SEM. PMI = postmortem interval; SCZ = schizo-
phrenia; MD = major depression; BD = bipolar depression.
Planned contrast, aP = 0.04 and bP = 0.07.
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Figure 1. Neuronal nitric oxide
synthase-immunoreact ive
(nNOS-IR) neurons in the
hippocampal formation. Pho-
tomicrographs illustrating
nNOS-IR neurons (10-µm sec-
tions) in the hippocampal CA4,
CA3, CA2, and CA1 subfields,
dentate gyrus (DG), subicu-
lum, and entorhinal cortex of
human brain. Immunohisto-
chemistry was performed us-
ing a monoclonal anti-nNOS
antibody (1:25, Transduction
Laboratories). Arrows indicate
nNOS-IR neurons. Bar = 100
µm for all panels.
Figure 2. Neuronal nitric oxide
synthase-immunoreact ive
(nNOS-IR) neurons in the hip-
pocampal CA1 subfield. Pho-
tomicrographs illustrating a
negative control (A) omitting
the primary nNOS antibody
from the staining protocol and
nNOS-IR neurons (B) in the
hippocampal CA1 subfield. Ar-
rows indicate nNOS-IR neu-
rons. Bar = 100 µm for panels
A and B.
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Table 2. Expression of neuronal nitric oxide synthase-immunoreactive (nNOS-IR) neurons in the human hippocampal formation of
schizophrenia (SCZ), major depression (MD), bipolar disorder (BD), and control groups.
Area nNOS-IR neurons/400 µm2 Nissl-stained neurons/400 µm2
Control   SCZ   MD BD Control SCZ   MD BD
CA4
Left 3.2 ± 0.4 3.7 ± 0.3 3.3 ± 0.4 3.2 ± 0.4 3.9 ± 0.3 3.4 ± 0.3 3.9 ± 0.3 3.4 ± 0.2
Right 2.7 ± 0.4 3.4 ± 0.5 3.8 ± 0.4 3.6 ± 0.4 3.6 ± 0.3 3.2 ± 0.4 3.3 ± 0.3 3.4 ± 0.3
CA3
Left 9.6 ± 0.5 9.6 ± 0.5 10.0 ± 0.5 8.8 ± 0.5 10.3 ± 0.8 11.0 ± 0.7 11.6 ± 0.7 10.2 ± 0.8
Right 9.8 ± 0.6 8.0 ± 0.7 9.7 ± 0.6 11.0 ± 0.5 10.8 ± 0.9 9.8 ± 1.1 9.6 ± 0.8 11.3 ± 0.7
CA2
Left 12.0 ± 0.8 10.5 ± 0.7 13.5 ± 0.74 12.3 ± 1.0 13.5 ± 0.8 14.7 ± 0.7 15.6 ± 0.8 13.9 ± 0.9
Right 12.0 ± 1.0 11.1 ± 1.2 12.0 ± 0.8 11.3 ± 0.8 13.9 ± 0.9 14.6 ± 1.3 13.5 ± 0.8 14.0 ± 0.8
CA1
Left 8.1 ± 0.5 8.7 ± 0.5 8.4 ± 0.5 8.5 ± 0.6 7.7 ± 0.7 8.7 ± 0.7 8.2 ± 0.7 7.9 ± 0.9
Right 6.6 ± 0.5 6.7 ± 0.8 9.2 ± 0.6** 8.4 ± 0.6* 8.9 ± 0.7 10.4 ± 1.0 9.0 ± 0.8 9.9 ± 0.7
Subiculum
Left 7.1 ± 0.5 6.2 ± 0.4 6.6 ± 0.4 6.1 ± 0.5 8.6 ± 0.6 8.2 ± 0.5 8.5 ± 0.6 8.4 ± 0.7
Right 5.9 ± 0.4 6.7 ± 0.6 6.8 ± 0.5 6.7 ± 0.4 8.7 ± 0.6 8.7 ± 0.7 9.1 ± 0.6 7.8 ± 0.6
ECII
Left 5.7 ± 0.8 5.9 ± 0.5 5.1 ± 0.5 5.5 ± 0.6 7.0 ± 0.4 7.6 ± 0.4 7.4 ± 0.4 7.3 ± 0.5
Right 6.3 ± 0.5 5.0 ± 0.8 5.9 ± 0.7 6.8 ± 0.5 7.6 ± 0.4 7.3 ± 0.7 7.6 ± 0.5 8.1 ± 0.4
ECIII
Left 6.2 ± 0.5 6.5 ± 0.4 6.6 ± 0.5 6.0 ± 0.5 6.9 ± 0.4 7.9 ± 0.4 8.2 ± 0.4 7.7 ± 0.5
Right 5.9 ± 0.4 6.1 ± 1.2 5.1 ± 0.7 6.4 ± 0.5 7.6 ± 0.4 7.8 ± 0.7 6.8 ± 0.5 7.5 ± 0.4
Data are reported as means ± SEM. See text for ANOVA details.
*P = 0.05, **P = 0.01, planned contrasts compared to control group in the right hemisphere.
Figure 3. Expression of neuronal nitric oxide synthase-immu-
noreactive (nNOS-IR) neurons in the CA1 and subiculum (Sub)
of hippocampal formation of schizophrenia (SCZ), major depres-
sion (MD), bipolar disorder (BD), and control groups. Observe
nNOS-IR expression in subfields with significant diagnosis by
side interactions. N = 6-8 subjects per group except 3-4 subjects
for SCZ in the right hemisphere. See text for ANOVA details. *P
= 0.05, **P = 0.01, planned contrasts compared to control group
in the right hemisphere.
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BD, had more nNOS-IR neurons in the right than controls,
with no differences in the left region (main analysis: F =
5.02; d.f. = 3.40; P < 0.05, contrasts vs controls in the right:
MD, P = 0.003; BD, P = 0.03). These effects were signifi-
cant in all analyses. This pattern was repeated in the
subiculum of BD and was statistically significant in two
subsidiary ANOVA tests (P < 0.05).
Clinical correlates
There were no group differences between affectively ill
subjects (i.e., MD combined with BD) on or off antidepres-
sants (N = 17 vs 18, respectively), benzodiazepines (N = 7
vs 19), or lithium (N = 6 vs 20), except in CA3 where lithium-
treated subjects had greater numbers of nNOS-IR neurons
than non-lithium-treated subjects (mean ± SEM/N: lithium-
treated, 10.9 ± 0.48/5; non-treated, 9.5 ± 0.28/18; t = 2.29;
P = 0.03).
There were no differences when comparing deaths by
suicide to death by natural causes within or between the
diagnostic groups.
Duration of illness showed no relationship with nNOS-
IR counts in the combined MD and BD groups or in the BD
group alone or in subjects on or off antidepressants.
Discussion
The present study provides evidence that nNOS ex-
pression is increased in CA1 and subiculum of patients
with affective disorders. This increase was significantly
more marked in samples from the right hemisphere and
was specific to the MD and BD groups, with no main effect
involving the SCZ group. While there were too few obser-
vations in the SCZ group to completely rule out right-
lateralized changes, there was no trend to an increase in
nNOS-IR neurons in CA1.
The pattern of nNOS expression observed in the hippo-
campal formation and entorhinal cortex in the present
study agrees with other reports (11,12). Although no quan-
titative description about the density of nNOS-IR neurons
in the hippocampus has been previously reported, there
appears to be a greater number of nNOS-IR neurons in the
present study than reported by others. The mouse mono-
clonal anti-nNOS antibody used has been shown to react
specifically with the 150-kDa human nNOS of the recombi-
nant protein or brain extract (Western blot), showing suffi-
cient isoform specificity to undertake reliable immunohis-
tochemical staining (30). We may have observed a greater
density because previous studies used different fixation
techniques (formalin-fixed tissue versus frozen sections)
and detected nNOS expression using polyclonal antibodies
or NADPH-diaphorase histochemistry.
We examined the possible influence of confounding
variables. Only time in formalin differed markedly between
groups and PMIs tended to show group differences (Table
1). However, no variable correlated with nNOS counts, so
group differences are unlikely to have contributed to group
differences in cell counts. Furthermore, these variables did
not differ between the SCZ group and the affectively ill
groups (MD and BD) while changes in nNOS counts were
limited to the affective groups.
The changes observed were more marked in the right
region and this may reflect the specialization of the right
hemisphere for affective processing in humans. Several
anatomical and functional changes in clinical studies of
MD are lateralized (31). O’Brien et al. (32) reported right
hippocampal atrophy in elderly patients with depression. A
recent meta-analysis found that right, but not left, hippo-
campal atrophy was associated with number of previous
episodes of depression (1). Furthermore, the right hemi-
sphere has been implicated in the pathogenesis of affec-
tive instability by studies on stroke and temporal lobe
epilepsy (33,34).
Stockmeier et al. (4) reported increased packing of
pyramidal neurons and glia in postmortem hippocampus
from the right hemispheres of patients with MD. They
concluded that loss of neuropil may occur in MD which may
contribute to the volume reduction noted in imaging stud-
ies. These investigators also observed a reduced soma
size in the hippocampal formation in depression, as did
Chana et al. (35) in some laminae of the cingulate cortex.
Increased packing due to loss of neuropil could explain our
finding of increased nNOS counts but only if loss of neuro-
pil was right-sided. We cannot exclude this possibility from
our study since we did not perform morphometric analysis
of the neurons. However, this explanation for increased
nNOS cell counts would also require the assumption of a
right lateralized change in cell size and, in addition, that
non-nNOS and nNOS-IR neurons show differential reduc-
tion in size. Another possible confounder is that differential
shrinkage of the sections may have occurred during histo-
logical processing in our affectively ill groups compared to
the control and SCZ groups, as reported by Stockmeier et
al. (4). However, this seems to be an unlikely confounder in
the present study since cells were counted throughout the
thickness of the sampling frame in all groups.
There was no evidence that increased nNOS-IR neu-
rons in the affective groups were attenuated in subjects
treated with antidepressants. However, the fact that ap-
proximately half the patients had died by suicide and that
others were symptomatic suggests that many patients had
not responded to treatment. Indeed, the lack of effect of
drugs on nNOS counts could indicate a failure to suppress
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decreased in the postmortem hippocampus but this oc-
curred in all diagnostic groups including SCZ, albeit in
different subregions (38). However, nNOS counts in any
hippocampal subfield did not show any tendency to de-
crease. We conclude that our results are not likely to be
due to cytotoxic effects of elevated glucocorticoid expo-
sure. However, it remains possible that increased nNOS
expression is initiated by glucocorticoids.
In conclusion, we provide evidence for an increased
number of neurons expressing nNOS-IR in the hippocam-
pus of patients with MD and BD. These results are compat-
ible with our main prediction that hippocampi from affectively
ill patients would show increased nNOS expression and
reinforce current interest in the NMDA-NO pathway as a
target for the pathophysiology of affective disorders and
antidepressant drug development.
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Increased numbers of nNOS-IR neurons in CA1 of MD
and BD seem to contradict the prediction that high circulat-
ing glucocorticoid concentrations in affective disorders
might have neurotoxic effects through NMDA-mediated
nNOS expression in the hippocampus (8). It is possible,
however, that nNOS-positive neurons are resistant to cyto-
toxicity and so become more densely packed as other
neurons die. Resistance of nNOS neurons has been re-
ported in Alzheimer’s disease (36), Huntington’s disease
(37) and NMDA-mediated neurotoxicity itself (8). Never-
theless, the asymmetric changes provide a strong argu-
ment against increased packing as the mechanism of
increased nNOS-IR neurons; it is difficult to envisage a
unilateral neurotoxic effect of stress. It is very likely that the
hippocampi from the MD and BD groups had undergone
prolonged exposure to glucocorticoids, especially because
many were from suicide victims. Indeed, it has been re-
ported that glucocorticoid receptor mRNA expression is
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